Amori, Renee E., Joseph Lau, and Anastassios G. Pittas. 2007. ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’. JAMA 298(2). doi: 10.1001/jama.298.2.194.
Amy Kennedy. 2013. ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’. PLoS ONE 8(3). doi: doi:  10.1371/journal.pone.0058861.
Anon. 2015a. ‘Minimizing Hypoglycemia in Diabetes: Table 1’. Diabetes Care 38(8):1583–91. doi: 10.2337/dc15-0279.
Anon. 2015b. ‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’. Diabetes Care 38(Supplement_1):S4–S4. doi: 10.2337/dc15-S003.
Anon. 2016a. ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’. New England Journal of Medicine 375(18):1799–1802. doi: 10.1056/NEJMc1611290.
Anon. 2016b. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375(18):1797–99. doi: 10.1056/NEJMc1611289.
Anon. 2016c. The Eatwell Guide. Public Health England.
Anon. n.d.-a. ‘A Randomised Trial of the Effect and Cost-Effectiveness of Early Intensive Mulitfactorial Therapy on 5-Year Cardiovascular Outcomes in Individuals with Screen-Detected Type 2 Diaberes:The Anglod-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) Study.’
Anon. n.d.-b. ‘[ARCHIVED CONTENT] Medicines Management: Everybody’s Business : Department of Health - Publications and Statistics’. Retrieved (http://webarchive.nationalarchives.gov.uk/20080205132320/http:/dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_082200).
Anon. n.d.-c. ‘Canagliflozin, Dapagliflozin and Empagliflozin as Monotherapies for Treating Type 2 Diabetes | 1-Recommendations | Guidance and Guidelines | NICE’.
Anon. n.d.-d. ‘Constructs of Depression and Distress in Diabetes: Time for an Appraisal- ClinicalKey’. Retrieved (https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357).
Anon. n.d.-e. ‘Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus (Review) TA151, July 2008’. Retrieved (http://www.nice.org.uk/guidance/ta151).
Anon. n.d.-f. ‘Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes June 2013’. Retrieved (http://www.nice.org.uk/guidance/ta288).
Anon. n.d.-g. ‘Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period  (NG3’. Retrieved (https://www.nice.org.uk/guidance/ng3).
Anon. n.d.-h. ‘Diagnosis and Management of Type 1 Diabetes in Children, Young People and Adults | Guidance and Guidelines | NICE’.
Anon. n.d.-i. ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists  in Type 2 Diabetes  Systematic Review and Mixed-Treatment Comparison Analysis’.
Anon. n.d.-j. ‘Exenatide Prolonged-Release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes | Guidance and Guidelines TA 248 Feb 2015’. Retrieved (https://www.nice.org.uk/guidance/ta248).
Anon. n.d.-k. ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’. Journal of Diabetes Science and Technology (Online) 3(4).
Anon. n.d.-l. ‘Guidelines’. Retrieved (https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes).
Anon. n.d.-m. ‘Liraglutide for the Treatment of Type 2 Diabetes Mellitus. TA203, Oct 2010’. Retrieved (https://www.nice.org.uk/guidance/ta203).
Anon. n.d.-n. ‘Liraglutide for the Treatment of Type 2 Diabetes Mellitus. TA203, Oct 2010’. Retrieved (https://www.nice.org.uk/guidance/ta203).
Anon. n.d.-o. ‘Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing’. Retrieved (https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/).
Anon. n.d.-p. ‘Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence.  CG76, Jan 2009’. Retrieved (https://www.nice.org.uk/guidance/cg76).
Anon. n.d.-q. ‘National Obesity Observatory’. Retrieved (http://www.noo.org.uk).
Anon. n.d.-r. ‘NHS Evidence: An Introduction’.
Anon. n.d.-s. ‘Obesity: Identification, Assessment and Management | Guidance and Guidelines | NICE’.
Anon. n.d.-t. ‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’.
Anon. n.d.-u. ‘Type 2 Diabetes: Lixisenatide | Evidence-Review | Advice | NICE’.
Anon. n.d.-v. ‘Type 2 Diabetes: Prevention in People at High Risk | Guidance and Guidelines | NICE’.
Anon. n.d.-w. ‘Unit 3 – Special Care Groups: A Practical Guide to Pregnancy Complicated by Diabetes - Diabetes & Primary Care’. Retrieved (http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview).
Anthony H. Barnett, Jenny Grice. 2013. New Mechanisms in Glucose Control. BMJ Books; 1 edition.
Atkinson, M. A. 2012. ‘The Pathogenesis and Natural History of Type 1 Diabetes’. Cold Spring Harbor Perspectives in Medicine 2(11):a007641–a007641. doi: 10.1101/cshperspect.a007641.
Avery, L., D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell. 2012. ‘Changing Physical Activity Behavior in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Behavioral Interventions’. Diabetes Care 35(12):2681–89. doi: 10.2337/dc11-2452.
Bailey, Clifford J., Jorge L. Gross, Anne Pieters, Arnaud Bastien, and James F. List. 2010. ‘Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial’. The Lancet 375(9733):2223–33. doi: 10.1016/S0140-6736(10)60407-2.
Bailey, Stephen. n.d. Academic Writing : A Handbook for International Students.
Barry, Vaughn W., Meghan Baruth, Michael W. Beets, J. Larry Durstine, Jihong Liu, and Steven N. Blair. 2014. ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’. Progress in Cardiovascular Diseases 56(4):382–90. doi: 10.1016/j.pcad.2013.09.002.
Bennett, Wendy L., Nisa M. Maruthur, Sonal Singh, Jodi B. Segal, Lisa M. Wilson, Ranee Chatterjee, Spyridon S. Marinopoulos, Milo A. Puhan, Padmini Ranasinghe, Lauren Block, Wanda K. Nicholson, Susan Hutfless, Eric B. Bass, and Shari Bolen. 2011. ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’. Annals of Internal Medicine 154(9). doi: 10.7326/0003-4819-154-9-201105030-00336.
Bergenstal, Richard M., William V. Tamborlane, Andrew Ahmann, John B. Buse, George Dailey, Stephen N. Davis, Carol Joyce, Tim Peoples, Bruce A. Perkins, John B. Welsh, Steven M. Willi, and Michael A. Wood. 2010. ‘Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes’. New England Journal of Medicine 363(4):311–20. doi: 10.1056/NEJMoa1002853.
Bethel, M. Angelyn, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, and Rury R. Holman. 2017. ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)’. Diabetes Care 40(4):494–501. doi: 10.2337/dc16-1135.
Beverley M Shields. 2015. ‘Can Clinical Features Be Used to Differentiate Type 1 from Type 2 Diabetes? A Systematic Review of the Literature’. BMJ Open 5(11). doi: doi:  10.1136/bmjopen-2015-009088.
Birkeland, Kåre I. 2015. ‘Hyperglycaemia in Pregnancy: Still a Lot to Learn’. The Lancet Diabetes & Endocrinology 3(10):752–53. doi: 10.1016/S2213-8587(15)00282-X.
Brown, Julie, Nisreen A. Alwan, Jane West, Stephen Brown, Christopher JD McKinlay, Diane Farrar, and Caroline A. Crowther. 1996. ‘Lifestyle Interventions for the Treatment of Women with Gestational Diabetes’. in Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd.
Buse, J. B., D. J. Drucker, K. L. Taylor, T. Kim, B. Walsh, H. Hu, K. Wilhelm, M. Trautmann, L. Z. Shen, and L. E. Porter. 2010. ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’. Diabetes Care 33(6):1255–61. doi: 10.2337/dc09-1914.
Buse, John B., Richard M. Bergenstal, Leonard C. Glass, Cory R. Heilmann, Michelle S. Lewis, Anita Y. M. Kwan, Byron J. Hoogwerf, and Julio Rosenstock. 2011. ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’. Annals of Internal Medicine 154(2). doi: 10.7326/0003-4819-154-2-201101180-00300.
Buse, John B., Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason H. Brett, Marcin Zychma, and Lawrence Blonde. 2009. ‘Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)’. The Lancet 374(9683):39–47. doi: 10.1016/S0140-6736(09)60659-0.
Capehorn, M., W. H. Polonsky, S. Edelman, A. Belton, S. Down, V. Gamerman, F. Nagel, J. Lee, and A. Alzaid. 2017. ‘Challenges Faced by Physicians When Discussing the Type 2 Diabetes Diagnosis with Patients: Insights from a Cross-National Study (IntroDia                              )’. Diabetic Medicine. doi: 10.1111/dme.13357.
Chimen, M., A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran. 2012. ‘What Are the Health Benefits of Physical Activity in Type 1 Diabetes Mellitus? A Literature Review’. Diabetologia 55(3):542–51. doi: 10.1007/s00125-011-2403-2.
Choudhary, Pratik, Neil R. Parrott, Linda Birtles, and Martin K. Rutter. 2012. ‘Islet Cell Transplantation: Current Status in the UK (2012)’. Practical Diabetes 29(7):280–85. doi: 10.1002/pdi.1707.
Copeland, K. C., J. Silverstein, K. R. Moore, G. E. Prazar, T. Raymer, R. N. Shiffman, S. C. Springer, V. V. Thaker, M. Anderson, S. J. Spann, and S. K. Flinn. 2013. ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’. PEDIATRICS 131(2):364–82. doi: 10.1542/peds.2012-3494.
Courtney, Hamish, Rahul Nayar, Chinnadorai Rajeswaran, and Ravi Jandhyala. 2017. ‘Long-Term Management of Type 2 Diabetes with Glucagon-like Peptide-1 Receptor Agonists’. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 10:79–87. doi: 10.2147/DMSO.S126763.
Creme, Phyllis, and Mary R. Lea. 2008. Writing At University: A Guide For Students. 3rd ed. Maidenhead: McGraw-Hill Education.
Davies, M., D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu. 2017. ‘Introduction of Biosimilar Insulins in Europe’. Diabetic Medicine 34(10):1340–53. doi: 10.1111/dme.13400.
Davies, M. J., S. Heller, T. C. Skinner, M. J. Campbell, M. E. Carey, S. Cradock, H. M. Dallosso, H. Daly, Y. Doherty, S. Eaton, C. Fox, L. Oliver, K. Rantell, G. Rayman, and K. Khunti. 2008. ‘Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) Programme for People with Newly Diagnosed Type 2 Diabetes: Cluster Randomised Controlled Trial’. BMJ 336(7642):491–95. doi: 10.1136/bmj.39474.922025.BE.
Dhatariya, K. K., C. Skedgel, and R. Fordham. 2017. ‘The Cost of Treating Diabetic Ketoacidosis in the UK: A National Survey of Hospital Resource Use’. Diabetic Medicine 34(10):1361–66. doi: 10.1111/dme.13427.
Diamant, Michaela, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, and Michael Trautmann. 2010. ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’. The Lancet 375(9733):2234–43. doi: 10.1016/S0140-6736(10)60406-0.
Dungan, Kathleen M., Santiago Tofé Povedano, Thomas Forst, José G. González González, Charles Atisso, Whitney Sealls, and Jessie L. Fahrbach. 2014. ‘Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial’. The Lancet 384(9951):1349–57. doi: 10.1016/S0140-6736(14)60976-4.
Fagin, James A., and Samuel A. Wells. 2016. ‘Biologic and Clinical Perspectives on Thyroid Cancer’. New England Journal of Medicine 375(11):1054–67. doi: 10.1056/NEJMra1501993.
Ferrari, M., M. Dal Cin, and M. Steele. 2017. ‘Self-Compassion Is Associated with Optimum Self-Care Behaviour, Medical Outcomes and Psychological Well-Being in a Cross-Sectional Sample of Adults with Diabetes’. Diabetic Medicine 34(11):1546–53. doi: 10.1111/dme.13451.
Gale, Edwin AM. 2013. ‘Is Type 2 Diabetes a Category Error?’ The Lancet 381(9881):1956–57. doi: 10.1016/S0140-6736(12)62207-7.
Gallwitz, Baptist, Julio Rosenstock, Thomas Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, Klaus A. Dugi, and Hans-Juergen Woerle. 2012. ‘2-Year Efficacy and Safety of Linagliptin Compared with Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Randomised, Double-Blind, Non-Inferiority Trial’. The Lancet 380(9840):475–83. doi: 10.1016/S0140-6736(12)60691-6.
Grammes, J., W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak. 2017. ‘Focus Group Study to Identify the Central Facets of Fear of Hypoglycaemia in People with Type 2 Diabetes Mellitus’. Diabetic Medicine. doi: 10.1111/dme.13506.
Gray, L. J., K. Khunti, C. Edwardson, S. Goldby, J. Henson, D. H. Morris, D. Sheppard, D. Webb, S. Williams, T. Yates, and M. J. Davies. 2012. ‘Implementation of the Automated Leicester Practice Risk Score in Two Diabetes Prevention Trials Provides a High Yield of People with Abnormal Glucose Tolerance’. Diabetologia 55(12):3238–44. doi: 10.1007/s00125-012-2725-8.
Gray, L. J., K. Khunti, E. G. Wilmot, T. Yates, and M. J. Davies. 2014. ‘External Validation of Two Diabetes Risk Scores in a Young UK South Asian Population’. Diabetes Research and Clinical Practice 104(3):451–58. doi: 10.1016/j.diabres.2014.03.018.
Green, Jennifer B., M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman. 2015. ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 373(3):232–42. doi: 10.1056/NEJMoa1501352.
Gregg, Edward W. 2017. ‘The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016’. Diabetes Care. doi: 10.2337/dci16-0055.
Hadjiconstantinou, Michelle, Jo Byrne, Danielle H. Bodicoat, Noelle Robertson, Helen Eborall, Kamlesh Khunti, and Melanie J. Davies. 2016. ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’. Journal of Medical Internet Research 18(10). doi: 10.2196/jmir.5991.
Harman-Boehm, Ilana. 2008. ‘Continuous Glucose Monitoring in Type 2 Diabetes’. Diabetes Research and Clinical Practice 82:S118–21. doi: 10.1016/j.diabres.2008.09.051.
Hartman, Yvonne A. W., Henry J. Jansen, Maria T. E. Hopman, Cees J. Tack, and Dick H. J. Thijssen. 2017. ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’. Diabetes Care 40(9):e120–21. doi: 10.2337/dc17-0787.
Heinonen, I., H. Helajärvi, K. Pahkala, O. J. Heinonen, M. Hirvensalo, K. Pälve, T. Tammelin, X. Yang, M. Juonala, V. Mikkilä, M. Kähönen, T. Lehtimäki, J. Viikari, and O. T. Raitakari. 2013. ‘Sedentary Behaviours and Obesity in Adults: The Cardiovascular Risk in Young Finns Study’. BMJ Open 3(6). doi: 10.1136/bmjopen-2013-002901.
Henson, Joseph. 2014. ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’
Hessler, D. M., L. Fisher, W. H. Polonsky, U. Masharani, L. A. Strycker, A. L. Peters, I. Blumer, and V. Bowyer. 2017. ‘Diabetes Distress Is Linked with Worsening Diabetes Management over Time in Adults with Type 1 Diabetes’. Diabetic Medicine 34(9):1228–34. doi: 10.1111/dme.13381.
Holt, Richard I. G. 2010a. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010b. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010c. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010d. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010e. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010f. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010g. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010h. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010i. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G. 2010j. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016a. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016b. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016c. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016d. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016e. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016f. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016g. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016h. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Holt, Richard I. G., Clive Cockram, Allan Flyvbjerg, and Barry J. Goldstein. 2016i. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated.
Inzucchi, Silvio E., Richard M. Bergenstal, John B. Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L. Peters, Apostolos Tsapas, Richard Wender, and David R. Matthews. 2015. ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’. Diabetes Care 38(1):140–49. doi: 10.2337/dc14-2441.
Jelinek, Herbert F., Andrew Stranieri, Andrew Yatsko, and Sitalakshmi Venkatraman. 2016. ‘Data Analytics Identify Glycated Haemoglobin Co-Markers for Type 2 Diabetes Mellitus Diagnosis’. Computers in Biology and Medicine 75:90–97. doi: 10.1016/j.compbiomed.2016.05.005.
John M Jakicic. 2005. ‘Physical Activity Considerations for the Treatment and Prevention of Obesity’. The American Journal of Clinical Nutrition 82(1):226S-229S.
Johnston, Bradley C., Steve Kanters, Kristofer Bandayrel, Ping Wu, Faysal Naji, Reed A. Siemieniuk, Geoff D. C. Ball, Jason W. Busse, Kristian Thorlund, Gordon Guyatt, Jeroen P. Jansen, and Edward J. Mills. 2014. ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’. JAMA 312(9). doi: 10.1001/jama.2014.10397.
Jones, A. G., and A. T. Hattersley. 2013. ‘The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes’. Diabetic Medicine 30(7):803–17. doi: 10.1111/dme.12159.
Kamlesh Khunti. 2015. ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’. PLoS ONE 10(9). doi: doi:  10.1371/journal.pone.0135702.
Kenneth Hodson. 2010. ‘Gestational Diabetes: Emerging Concepts in Pathophysiology’. Obstetric Medicine 3(4). doi: doi:  10.1258/om.2010.100025.
Latika Sahu. 2009. ‘Comparison of the American Diabetes Association and World Health Organization Criteria for Gestational Diabetes Mellitus and the Outcomes of Pregnancy’. Obstetric Medicine 2(4). doi: doi:  10.1258/om.2009.080049.
Lee, I.-Min. 2010. ‘Physical Activity and Weight Gain Prevention’. JAMA 303(12). doi: 10.1001/jama.2010.312.
Leelarathna, L., S. A. Roberts, A. Hindle, K. Markakis, T. Alam, A. Chapman, J. Morris, A. Urwin, P. Jinadev, and M. K. Rutter. 2017. ‘Comparison of Different Insulin Pump Makes under Routine Care Conditions in Adults with Type 1 Diabetes’. Diabetic Medicine 34(10):1372–79. doi: 10.1111/dme.13412.
Leff, D. R., and D. Heath. 2009. ‘Surgery for Obesity in Adulthood’. BMJ 339(sep22 1):b3402–b3402. doi: 10.1136/bmj.b3402.
Levin, Philip A., Hiep Nguyen, Eric Wittbrodt, and Seoyoung C. Kim. 2017. ‘Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review of Comparative Effectiveness Research’. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 10:123–39. doi: 10.2147/DMSO.S130834.
Marso, Steven P., Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L. Warren, Vincent Woo, Oluf Hansen, Anders G. Holst, Jonas Pettersson, and Tina Vilsbøll. 2016. ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’. New England Journal of Medicine. doi: 10.1056/NEJMoa1607141.
Marso, Steven P., Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F. E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Lasse S. Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, and John B. Buse. 2016a. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375(4):311–22. doi: 10.1056/NEJMoa1603827.
Marso, Steven P., Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F. E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Lasse S. Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, and John B. Buse. 2016b. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375(4):311–22. doi: 10.1056/NEJMoa1603827.
Merlin C. Thomas. 2016. ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’. Diabetes Therapy 7(3). doi: doi:  10.1007/s13300-016-0189-4.
Min, Se Hee, Jeong-Hwa Yoon, Seokyung Hahn, and Young Min Cho. 2017. ‘Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-Analysis’. Diabetes/Metabolism Research and Reviews 33(1). doi: 10.1002/dmrr.2818.
Mishriky, Basem M., Doyle M. Cummings, and Robert J. Tanenberg. 2015. ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’. Diabetes Research and Clinical Practice 109(2):378–88. doi: 10.1016/j.diabres.2015.05.025.
Moreno-Castilla, Cristina, Didac Mauricio, and Marta Hernandez. 2016. ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’. Current Diabetes Reports 16(4). doi: 10.1007/s11892-016-0717-7.
Narendran, P., N. Jackson, A. Daley, D. Thompson, K. Stokes, S. Greenfield, M. Charlton, M. Curran, T. P. J. Solomon, A. Nouwen, S. I. Lee, A. R. Cooper, M. Mostazir, R. S. Taylor, A. Kennedy, and R. C. Andrews. 2017. ‘Exercise to Preserve β-Cell Function in Recent-Onset Type 1 Diabetes Mellitus (EXTOD) - a Randomized Controlled Pilot Trial’. Diabetic Medicine 34(11):1521–31. doi: 10.1111/dme.13439.
Nauck, M. A., G. Meininger, D. Sheng, L. Terranella, and P. P. Stein. 2007. ‘Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea, Glipizide, in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone: A Randomized, Double-Blind, Non-Inferiority Trial’. Diabetes, Obesity and Metabolism 9(2):194–205. doi: 10.1111/j.1463-1326.2006.00704.x.
Nauck, Michael A., and Juris J. Meier. 2016. ‘The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions’. The Lancet Diabetes & Endocrinology 4(6):525–36. doi: 10.1016/S2213-8587(15)00482-9.
Nauck, Michael, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, and Zvonko Milicevic. 2014. ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’. Diabetes Care 37(8):2149–58. doi: 10.2337/dc13-2761.
Nissen, Steven E., and Kathy Wolski. 2007. ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’. New England Journal of Medicine 356(24):2457–71. doi: 10.1056/NEJMoa072761.
Noctor, Eoin, and Fidelma Dunne. 2015. ‘Postnatal Testing Following Gestational Diabetes’. The Lancet Diabetes & Endocrinology 3(10):761–62. doi: 10.1016/S2213-8587(15)00322-8.
Nolan, Christopher J., Neil B. Ruderman, Steven E. Kahn, Oluf Pedersen, and Marc Prentki. 2015. ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’. Diabetes 64(3):673–86. doi: 10.2337/db14-0694.
Paul Craddy. 2014. ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’. Diabetes Therapy 5(1). doi: doi:  10.1007/s13300-014-0061-3.
Perrin, N. E., M. J. Davies, N. Robertson, F. J. Snoek, and K. Khunti. 2017. ‘The Prevalence of Diabetes-Specific Emotional Distress in People with Type 2 Diabetes: A Systematic Review and Meta-Analysis’. Diabetic Medicine 34(11):1508–20. doi: 10.1111/dme.13448.
Persaud, Shanta J., and Peter M. Jones. 2016. ‘A Wake-up Call for Type 2 Diabetes?’ New England Journal of Medicine 375(11):1090–92. doi: 10.1056/NEJMcibr1607950.
Pickup, John C. 2012. ‘Insulin-Pump Therapy for Type 1 Diabetes Mellitus’. New England Journal of Medicine 366(17):1616–24. doi: 10.1056/NEJMct1113948.
Qin, Li, Mirjam J. Knol, Eva Corpeleijn, and Ronald P. Stolk. 2010. ‘Does Physical Activity Modify the Risk of Obesity for Type 2 Diabetes: A Review of Epidemiological Data’. European Journal of Epidemiology 25(1):5–12. doi: 10.1007/s10654-009-9395-y.
Rasouli, B., T. Andersson, P. O. Carlsson, R. Hjort, J. E. Löfvenborg, M. Martinell, L. Groop, T. Tuomi, and S. Carlsson. 2017. ‘Serious Life Events and the Risk of Latent Autoimmune Diabetes in Adults (LADA) and Type 2 Diabetes’. Diabetic Medicine 34(9):1259–63. doi: 10.1111/dme.13410.
Riddle, M. C., R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, L. Ping, J. Ye, and J. Rosenstock. 2013. ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)’. Diabetes Care 36(9):2489–96. doi: 10.2337/dc12-2454.
Rinki Murphy. 2015. ‘Monogenic Diabetes and Pregnancy’. Obstetric Medicine 8(3). doi: doi:  10.1177/1753495X15590713.
Rizos, Christos V., Anastazia Kei, and Moses S. Elisaf. 2016. ‘The Current Role of Thiazolidinediones in Diabetes Management’. Archives of Toxicology 90(8):1861–81. doi: 10.1007/s00204-016-1737-4.
Rotz, M. E., V. S. Ganetsky, S. Sen, and T. F. Thomas. 2015. ‘Implications of Incretin-Based Therapies on Cardiovascular Disease’. International Journal of Clinical Practice 69(5):531–49. doi: 10.1111/ijcp.12572.
Ryder, Bob, John McKnight, Andrew Blann, Ketan Dhatariya, Rob Gregory, Tony Robinson, Susannah Rowles, Patrick Sharp, Peter H. Winocour, and Chris Walton. 2013. ‘ABCD Position Statement on GLP-1 Based Therapies and Pancreatic Damage’. Practical Diabetes 30(9):388–91. doi: 10.1002/pdi.1816.
S M Attard. 2015. ‘Implications of Iron Deficiency/Anemia on the Classification of Diabetes Using HbA1c’. Nutrition & Diabetes 5(6). doi: doi:  10.1038/nutd.2015.16.
Sallis, James F., Fiona Bull, Regina Guthold, Gregory W. Heath, Shigeru Inoue, Paul Kelly, Adewale L. Oyeyemi, Lilian G. Perez, Justin Richards, and Pedro C. Hallal. 2016. ‘Progress in Physical Activity over the Olympic Quadrennium’. The Lancet 388(10051):1325–36. doi: 10.1016/S0140-6736(16)30581-5.
Samuel, Varman T., and Gerald I. Shulman. 2012. ‘Intergrating Mechanisms  for Insulin Resistance: Common Threads and Missing Links’. Cell 148(5):852–71. doi: 10.1016/j.cell.2012.02.017.
Schauer, Philip R., Deepak L. Bhatt, John P. Kirwan, Kathy Wolski, Ali Aminian, Stacy A. Brethauer, Sankar D. Navaneethan, Rishi P. Singh, Claire E. Pothier, Steven E. Nissen, and Sangeeta R. Kashyap. 2017a. ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’. New England Journal of Medicine 376(7):641–51. doi: 10.1056/NEJMoa1600869.
Schauer, Philip R., Deepak L. Bhatt, John P. Kirwan, Kathy Wolski, Ali Aminian, Stacy A. Brethauer, Sankar D. Navaneethan, Rishi P. Singh, Claire E. Pothier, Steven E. Nissen, and Sangeeta R. Kashyap. 2017b. ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’. New England Journal of Medicine 376(7):641–51. doi: 10.1056/NEJMoa1600869.
Schauer, Philip R., Sangeeta R. Kashyap, Kathy Wolski, Stacy A. Brethauer, John P. Kirwan, Claire E. Pothier, Susan Thomas, Beth Abood, Steven E. Nissen, and Deepak L. Bhatt. 2012. ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’. New England Journal of Medicine 366(17):1567–76. doi: 10.1056/NEJMoa1200225.
Schwartz, Stanley S., Solomon Epstein, Barbara E. Corkey, Struan F. A. Grant, James R. Gavin, and Richard B. Aguilar. 2016. ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’. Diabetes Care 39(2):179–86. doi: 10.2337/dc15-1585.
Sivasubramaniyam, S., S. A. Amiel, and P. Choudhary. 2017. ‘Proportion of Daily Capillary Blood Glucose Readings Required in the Target Range for Target Glycaemic Control: Shift of Focus from Target Range to Proportion in Range’. Diabetic Medicine 34(10):1456–60. doi: 10.1111/dme.13438.
Sjöström, Lars, Anna-Karin Lindroos, Markku Peltonen, Jarl Torgerson, Claude Bouchard, Björn Carlsson, Sven Dahlgren, Bo Larsson, Kristina Narbro, Carl David Sjöström, Marianne Sullivan, and Hans Wedel. 2004. ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’. New England Journal of Medicine 351(26):2683–93. doi: 10.1056/NEJMoa035622.
Srinivasan, P., G. C. Huang, S. A. Amiel, and N. D. Heaton. 2007. ‘Islet Cell Transplantation’. Postgraduate Medical Journal 83(978):224–29. doi: 10.1136/pgmj.2006.053447.
Steven, S., and R. Taylor. 2015. ‘Restoring Normoglycaemia by Use of a Very Low Calorie Diet in Long- and Short-Duration Type 2 Diabetes’. Diabetic Medicine 32(9):1149–55. doi: 10.1111/dme.12722.
Steven, Sarah, Kieren G. Hollingsworth, Ahmad Al-Mrabeh, Leah Avery, Benjamin Aribisala, Muriel Caslake, and Roy Taylor. 2016. ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’. Diabetes Care 39(5):808–15. doi: 10.2337/dc15-1942.
Stewart, Zoe A., Malgorzata E. Wilinska, Sara Hartnell, Rosemary C. Temple, Gerry Rayman, Katharine P. Stanley, David Simmons, Graham R. Law, Eleanor M. Scott, Roman Hovorka, and Helen R. Murphy. 2016. ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’. New England Journal of Medicine 375(7):644–54. doi: 10.1056/NEJMoa1602494.
Tanner, Michael. 2016. ‘Review: In Type 2 Diabetes, Adding Dipeptidyl Peptidase-4 Inhibitors to Sulphonylureas Increases Hypoglycemia’. Annals of Internal Medicine 165(4). doi: 10.7326/ACPJC-2016-165-4-020.
Tao, L., E. C. F. Wilson, N. J. Wareham, A. Sandbaek, G. E. H. M. Rutten, T. Lauritzen, K. Khunti, M. J. Davies, K. Borch-Johnsen, S. J. Griffin, and R. K. Simmons. 2015. ‘Cost-Effectiveness of Intensive Multifactorial Treatment Compared with Routine Care for Individuals with Screen-Detected Type 2 Diabetes: Analysis of the ADDITION-UK Cluster-Randomized Controlled Trial’. Diabetic Medicine 32(7):907–19. doi: 10.1111/dme.12711.
Umpierre, Daniel. 2011. ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA                              Levels in Type 2 Diabetes’. JAMA 305(17). doi: 10.1001/jama.2011.576.
Villani, M., B. de Courten, and S. Zoungas. 2017. ‘Emergency Treatment of Hypoglycaemia: A Guideline and Evidence Review’. Diabetic Medicine 34(9):1205–11. doi: 10.1111/dme.13379.
Vloemans, A. F., C. A. J. van Beers, M. de Wit, W. Cleijne, S. M. Rondags, P. H. Geelhoed-Duijvestijn, M. H. H. Kramer, E. H. Serné, and F. J. Snoek. 2017. ‘Keeping Safe. Continuous Glucose Monitoring (CGM) in Persons with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia: A Qualitative Study’. Diabetic Medicine 34(10):1470–76. doi: 10.1111/dme.13429.
Wanner, Christoph, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, and Bernard Zinman. 2016. ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’. New England Journal of Medicine 375(4):323–34. doi: 10.1056/NEJMoa1515920.
William H. Polonsky,Lawrence Fisher,Jay Earles,R. James Dudl,Joel Lees,Joseph Mullan. n.d. ‘Assessing Psychosocial Distress in Diabetes: Development of the Diabetes Distress Scale’. Diabetes Care.
Yates, T., and M. J. Davies. 2017. ‘Physical Activity and Type 1 Diabetes: An Underused Therapy’. Diabetic Medicine 34(11):1498–99. doi: 10.1111/dme.13445.
Yeh, James S., Robert F. Kushner, and Gordon D. Schiff. 2016. ‘Obesity and Management of Weight Loss’. New England Journal of Medicine 375(12):1187–89. doi: 10.1056/NEJMclde1515935.
Young-Hyman, Deborah, Mary de Groot, Felicia Hill-Briggs, Jeffrey S. Gonzalez, Korey Hood, and Mark Peyrot. 2017. ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’. Diabetes Care 40(2):287.1-287. doi: 10.2337/dc17-er02.
Zaccardi, Francesco, David R. Webb, Thomas Yates, and Melanie J. Davies. 2016. ‘Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective’. Postgraduate Medical Journal 92(1084):63–69. doi: 10.1136/postgradmedj-2015-133281.